Medicare Alzheimer's Drug Uptake Falls Short as Estrogen Patch Shortages Mount

References

1. 1.American Society of Health-System Pharmacists. (2026). Drug Shortage Database. ASHP. https://www.ashp.org/drug-shortages
2. 2.Baber, R. J., Panay, N., Fenton, A., et al. (2016). 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 19(2), 109-150. https://doi.org/10.1080/13697137.2016.1181613
3. 3.Rabinovici, G. D. (2023). Controversy and progress in Alzheimer's disease — FDA approval of aducanumab. New England Journal of Medicine, 385(9), 771-774. https://doi.org/10.1056/NEJMp2111320
4. 4.Silverman, E. (2026). Pharmalittle: We're reading about Medicare and Alzheimer's drugs, estrogen patch shortages, and more. STAT News. https://www.statnews.com/pharmalot/2026/05/11/medicare-alzheimers-drugs-estrogen-patch-shortage/
5. 5.Sims, J. R., Zimmer, J. A., Evans, C. D., et al. (2023). Donanemab in early symptomatic Alzheimer disease. JAMA, 330(6), 512-527. https://doi.org/10.1001/jama.2023.13239
6. 6.Stuenkel, C. A., Davis, S. R., Gompel, A., et al. (2015). Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. https://doi.org/10.1210/jc.2015-2236
7. 7.Tucker, M. E. (2022). Drug shortages: A persistent problem with no easy solutions. JAMA, 327(16), 1543-1544. https://doi.org/10.1001/jama.2022.11928
8. 8.van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in early Alzheimer's disease. New England Journal of Medicine, 388(1), 9-21. https://doi.org/10.1056/NEJMoa2212948